Display Settings:

Format

Send to:

Choose Destination
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.

Treatment of systemic lupus erythematosus with epratuzumab.

Author information

  • 1Dept. Dermatology CSK MSWiA, Warsaw, Poland. paul-tr@wp.pl

Abstract

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by abnormalities in the activity of B-cells and T-cells. A novel specific treatment for autoimmune diseases is B-cell depletion with monoclonal antibodies. Epratuzumab is a monoclonal antibody that targets CD22 antigen on B-cells. Initial phase II and two terminated early phase III studies suggest that treatment of systemic lupus erythematosus with this immunomodulatory agent is effective, well tolerated and significantly improves the patient's quality of life. In vitro studies and clinical trials with non-Hodgkin lymphoma patients indicate epratuzumab can potentially serve as a complementary drug in combination therapy with another inhibitor of B-cell activity, rituximab, which is a monoclonal anti-CD20 antibody.

© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

PMID:
21219397
[PubMed - indexed for MEDLINE]
PMCID:
PMC3040537
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk